open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-15
Get Citation

Usefulness of non-vitamin K antagonist anticoagulants in therapy of venous thromboembolism — tips for choice of oral treatment

Marzanna Paczyńska, Michał Ciurzyński
DOI: 10.5603/FC.a2016.0091
·
Folia Cardiologica 2016;11(5):421-426.

open access

Vol 11, No 5 (2016)
Review Papers
Published online: 2016-09-15

Abstract

Patients with venous thromboembolism require prolonged or often life-long anticoagulant treatment. The treatment may involve with low molecular weight heparins or oral anticoagulants. Vitamin K antagonists were standard oral therapy for years. Nowadays available non-vitamin K antagonist anticoagulants have proved their efficacy and safety in many trials. They present a good alternative for the standard therapy. In this article we provide tips for choice of oral treatment depending on individual risk.

Abstract

Patients with venous thromboembolism require prolonged or often life-long anticoagulant treatment. The treatment may involve with low molecular weight heparins or oral anticoagulants. Vitamin K antagonists were standard oral therapy for years. Nowadays available non-vitamin K antagonist anticoagulants have proved their efficacy and safety in many trials. They present a good alternative for the standard therapy. In this article we provide tips for choice of oral treatment depending on individual risk.

Get Citation

Keywords

venous thromboembolism, anticoagulant therapy, oral anticoagulants

About this article
Title

Usefulness of non-vitamin K antagonist anticoagulants in therapy of venous thromboembolism — tips for choice of oral treatment

Journal

Folia Cardiologica

Issue

Vol 11, No 5 (2016)

Pages

421-426

Published online

2016-09-15

DOI

10.5603/FC.a2016.0091

Bibliographic record

Folia Cardiologica 2016;11(5):421-426.

Keywords

venous thromboembolism
anticoagulant therapy
oral anticoagulants

Authors

Marzanna Paczyńska
Michał Ciurzyński

References (16)
  1. Konstantinides SV, Torbicki A, Agnelli G, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014; 35(43): 3033-3069–69a-69k.
  2. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011; 123(13): 1436–1450.
  3. Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014; 53(1): 1–16.
  4. Lip GYH, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J. 2014; 35(28): 1844–1855.
  5. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342–2352.
  6. Schulman S, Goldhaber SZ, Kearon C, et al. RE-COVER II Trial Investigators, RE-MEDY Trial Investigators, RE-SONATE Trial Investigators, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342–2352.
  7. Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 1287–1297.
  8. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9): 799–808.
  9. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406–1415.
  10. Jiménez D, Aujesky D, Moores L, et al. RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010; 170(15): 1383–1389.
  11. Schoepf UJ, Kucher N, Kipfmueller F, et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation. 2004; 110(20): 3276–3280.
  12. Becattini C, Agnelli G, Vedovati MC, et al. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J. 2011; 32(13): 1657–1663.
  13. Paczyńska M, Kurnicka K, Lichodziejewska B, et al. Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy: an academic centre experience. Kardiol Pol. 2016; 74(7): 650–656.
  14. Yeh CH, Gross PL, Weitz JI. Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood. 2014; 124(7): 1020–1028.
  15. Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist. 2014; 19(1): 82–93.
  16. van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014; 12(3): 320–328.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl